Cardiol Therapeutics Concludes MAvERIC Phase II Study On Recurrent Pericarditis, With Findings To Be Presented At The 2024 American Heart Association Scientific Sessions.
Portfolio Pulse from Benzinga Newsdesk
Cardiol Therapeutics has completed its MAvERIC Phase II study on recurrent pericarditis. The findings will be presented at the 2024 American Heart Association Scientific Sessions.
September 10, 2024 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cardiol Therapeutics has concluded its MAvERIC Phase II study on recurrent pericarditis, with results to be presented at a major scientific conference in 2024.
The completion of a Phase II study is a significant milestone for a biotech company, potentially leading to further development and partnerships. Presentation at a major conference could increase visibility and investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90